Memorial Sloan Kettering Cancer Center | Strategic Alliance Partners

May 11, 2015

The sheer number of survivors- nearly 15 million in the United States, or 4% of the population-has brought greater attention to ensuring that cancer treatment does not cause other harms, since cancer patients are not only living but also living longer.

April 23, 2015

Population-based cancer screening using genetic sequencing technology is an idea worthy of careful consideration, but there are many challenges to implementing such a program.

April 11, 2015

Jedd D. Wolchok, MD, PhD, played an important role in the development of ipilimumab, the first drug to target an immune checkpoint as an anticancer strategy. He was honored in the Melanoma category with a 2014 Giants of Cancer Care® award.

April 07, 2015

A biomarker panel containing circulating tumor cell number and LDH level was shown to be a surrogate for overall survival in patients with metastatic castration-resistant prostate cancer.

April 02, 2015

Clifford A. Hudis, MD, chief, Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, discusses the challenges with approaching the topic of obesity in patients with cancer.

March 30, 2015

Jedd Wolchok, MD, PhD, chief, of Melanoma and Immunotherapeutics Service, Memorial Sloan Kettering Cancer Center, discusses the toxicities associated with immunotherapy.

March 23, 2015

Mario E. Lacouture, MD, a dermatologist with Memorial Sloan Kettering Cancer Center, explains how providers can manage adverse events that result from melanoma therapies.

March 12, 2015

Martin H. Voss, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses early efficacy signals in the phase I/II DART study.

February 27, 2015

In an analysis of phase III data, the 5-year survival rate with ipilimumab plus dacarbazine in patients with advanced melanoma was 18.2% versus 8.8% with dacarbazine alone.

February 25, 2015

Steven M. Horwitz, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses some of the challenges oncologists face with T-cell lymphoma.

February 08, 2015

Amid continuing excitement over the potential for PD-1 pathway immune checkpoint blockade strategies in anticancer therapies, research presented at the 2014 American Society of Hematology (ASH) Annual Meeting helped established a foundation for the use of anti- PD-1/PD-L1 agents in hematologic malignancies.

January 13, 2015

Jedd D. Wolchok, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses remaining questions regarding immunotherapies for the treatment of melanoma.

January 13, 2015

Approximately 22,000 women will be diagnosed with epithelial ovarian cancer (EOC) in the United States in 2014, making it the nation's second most common gynecologic malignancy.1 The cancer, which often presents at an advanced stage, causes more deaths than any other type of gynecologic malignancy.

January 07, 2015

For more than two decades, Kenneth Offit, MD, MPH, has been researching the molecular genetic factors that increase cancer risk, notably concerning germline BRCA mutations in breast and ovarian cancer, with a focus on potential preventive surgical remedies and screening programs for women at hereditary risk.

October 15, 2014

Clifford A. Hudis, MD, chief, Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, professor of medicine, Weill Cornell Medical College, discusses obesity and its relation to breast cancer.

October 06, 2014

In 2014, the amount of medical and other information has only increased, and mobile devices such as smartphones and tablets make it even easier to access that data.

September 23, 2014

At the 2014 ASCO meeting, OncologyLive sat down with Jimmie C. Holland, MD, the Wayne E. Chapman Chair in Psychiatric Oncology at Memorial Sloan Kettering Cancer Center and the recipient of the 2014 Giants of Cancer Careâ„¢ Award for her pioneering contributions in the field of supportive care.

September 22, 2014

Although universal insurance coverage for postmastectomy breast reconstruction has been mandated since 1998, a new study has found that the persistently high rates of American women who choose not to undergo reconstruction surgery are due primarily to patient preferences and not a lack of awareness.

August 07, 2014

At Memorial Sloan Kettering, we offer a variety of clinical trials for patients with mesothelioma at all stages of their disease.

July 23, 2014

Although malignant pleural mesothelioma (MPM) remains a rare disease, Memorial Sloan Kettering Cancer Center has considerable experience with this malignancy, and our specialists are at the forefront of translating new approaches for the treatment of patients with mesothelioma into the clinic.